|Expense Ratio (net)||N/A|
|Last Cap Gain||N/A|
|Morningstar Risk Rating||N/A|
|Beta (3Y Monthly)||N/A|
|5y Average Return||N/A|
|Average for Category||N/A|
PETACH TIKVA, Israel , April 1, 2019 /CNW/ - Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (GUD.TO) ("Knight" or the "Company"), today announced that it has nominated six exceptional pharmaceutical industry leaders (the "Nominees") for election to Knight's Board of Directors (the "Board") at the Company's 2019 annual general meeting, in accordance with the Company's Advanced Notice By-Law. Other than Medison's CEO, Meir Jakobsohn, who has served on the Knight Board since 2015, none of the Nominees has any ties to Knight or Medison.
Legendary investor Seth Klarman (Trades, Portfolio) disclosed Thursday that his long-term stake in kidney care company Keryx Biopharmaceuticals (KERX) closed as it converted into a stake in Akebia Therapeutics (AKBA) upon the merger of the two companies. Warning! GuruFocus has detected 2 Warning Signs with TBPH.
Akebia Therapeutics Inc (NASDAQ: AKBA ) announced shareholder approval this week for its merger with Keryx Biopharmaceuticals (NASDAQ: KERX ). The Analyst Analyst Reni Benjamin of Raymond James maintains ...
Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that Keryx stockholders voted in favor of adopting the merger agreement among Keryx and inter alia Akebia Therapeutics, Inc. Separately today, Akebia announced that its stockholders voted to approve the share issuance proposal relating to the merger with Keryx at a special meeting of Akebia stockholders.
Keryx Biopharma (KERX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.